Insilico Medicine (HKG:3696) said Tuesday it has initiated a phase 3 clinical trial of rentosertib in China, according to a Wednesday filing with the Hong Kong bourse.
Shares of the biotechnology company rose 3% in recent trade.
The trial is designed to evaluate the efficacy and safety of the drug in treating idiopathic pulmonary fibrosis, a lung disease.